Carlyle Group’s Adicet Bio ACET Stock Holding History

Carlyle Group’s Portfolio ACET Stock Details ACET Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.59M	Hold	184,295	–	–	0.02%	9
2026 Q1	$1.26M	Hold	184,295	–	–	0.01%	11
2025 Q4	$1.54M	Hold	184,295	–	–	0.01%	12
2025 Q3	$2.39M	Hold	184,295	–	–	0.06%	10
2025 Q2	$1.8M	Hold	184,295	–	–	0.04%	14
2025 Q1	$2.28M	Hold	184,295	–	–	0.06%	16
2024 Q4	$2.84M	Hold	184,295	–	–	0.07%	18
2024 Q3	$4.25M	Hold	184,295	–	–	0.45%	13
2024 Q2	$3.6M	Hold	184,295	–	–	0.34%	18
2024 Q1	$6.9M	Buy	184,295 +52,083	+39%	+$2.15M	0.44%	15
2023 Q4	$3.98M	Hold	132,212	–	–	0.19%	18
2023 Q3	$2.88M	Hold	132,212	–	–	0.12%	20
2023 Q2	$5.12M	Hold	132,212	–	–	0.18%	17
2023 Q1	$12.2M	Buy	+132,212	New	+$16.6M	0.36%	15

Other funds holding ACET

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

Carlyle Group's ACET Position: Q2 2026 in Review

Carlyle Group held its Adicet Bio (ACET) position steady in Q2 2026 at 184,295 shares worth $1.59M. The position accounts for 0.02% of the portfolio, ranked #9.

Carlyle Group first reported a position in ACET in Q1 2023 and has held it in 14 quarters since. The position peaked at $12.2M in Q1 2023. 56 funds tracked by Wall St. Rank hold ACET as of Q2 2026.

Carlyle Group held 184,295 shares of Adicet Bio worth $1.59M as of Q2 2026.
Carlyle Group left its Adicet Bio share count unchanged in Q2 2026.
Adicet Bio made up 0.02% of Carlyle Group's portfolio in Q2 2026, its #9 holding.
Carlyle Group first reported a position in Adicet Bio in Q1 2023 and has held it in 14 quarters since.
Carlyle Group's Adicet Bio position peaked at $12.2M in Q1 2023.
56 funds tracked by Wall St. Rank held Adicet Bio as of Q2 2026.

Based on Carlyle Group's 13F filing for Q2 2026, filed 7 Aug 2026.